Interleukin I (IL-1) may be a key mediator of inflammation and tissue damage in inflammatory bowel disease (IBD). In rabbits with immune complex-induced colitis, IL-la and (3 mRNA levels were detectable at 4 h, peaked at 12 but were absent at 96 h after the induction of colitis. Colonic IL-1 tissue levels were measured by specific radioimmunoassays. IL-la was significantly elevated at 4 h (9.4±1.5 ng/g colon), progressively increased at 48 h (31±5.8 ng/g) and then decreased by 96 h (11.5±3.4 ng/g). IL-lft levels were 2.0±0.5 ng/g colon at 4 h, 5.0±1.6 ng/g at 48 h and undetectable by 96 h. By comparison, colonic levels of PGE2 and LTB4 were unchanged during the first 12 h and did not become elevated until 24 h. IL-la levels were highly correlated with inflammation (r = 0.885, P < 0.0001), edema (r = 0.789, P < 0.0001) and necrosis (r = 0.752, P < 0.0005). Treatment with a specific IL-1 receptor antagonist (IL-Ira) before and during the first 33 h after the administration of immune complexes markedly reduced inflammatory cell infiltration index (from 3.2±0.4 to 1.4±0.3, P < 0.02), edema (from 2.2±0.4 to 0.6±0.3, P < 0.01) and necrosis (from 43±10% to 6.6±3.2%, P < 0.03) compared to vehicle-matched colitis animals. These studies demonstrate 
Introduction
Interleukin-1 (IL-1) is a polypeptide cytokine produced during inflammation and injury, that possesses a wide spectrum of immunologic and nonimmunologic activities (1) . Two distinct gene products of IL-I have been identified: IL-lI3, which is secreted by cells, and IL-la, which is primarily a cell-associated protein (2) (3) (4) . Both forms share the same spectrum of biological activities and recognize the same cell surface receptors (reviewed in 1). Interest has focused on the role of IL-1 as an inflammatory mediator in chronic and acute diseases (5, 6) . Elevated IL-I levels have been reported in synovial fluid and plasma from patients with various arthritides (7) (8) (9) . In addition, patients with acute meningitis, septic shock, or burn injuries often show increased circulating levels of IL-I (10, 11) .
Increased IL-I production by blood mononuclear cells has been described in several pathologic conditions including rheumatoid arthritis and Crohn's disease (12) (13) (14) .
Several of the biological properties of IL-I are relevant to inflammatory bowel disease. When injected in rabbits, IL-I induces fever, neutrophilia, decreased plasma iron, zinc and albumin levels, and synthesis of acute-phase proteins (1) . IL-I attracts leukocytes into inflamed tissues (15) and stimulates prostaglandin synthesis by its ability to induce cyclooxygenase gene expression (16) . Thus, systemic and local IL-I production may initiate or contribute to the inflammatory response in colitis and could play a role in the pathogenesis ofthis disease. Our recent studies are consistent with this hypothesis, as IL-I perfused in or incubated with rabbit colons induced prostaglandin and thromboxane production (17) .
We have previously used the rabbit model of formalin-immune complex colitis to investigate the role of arachidonic acid-derived inflammatory mediators and to evaluate therapeutic strategies in colitis (18) (19) (20) . The availability of specific cDNA probes and radioimmunoassays for rabbit IL-i a and IL-1(3 (21, 22) , as well as a specific IL-I receptor antagonist (IL-Ira) (23, 24) offers an opportunity to study the role of IL-I in this model. Therefore, the aims of the present study were to examine the time course of IL-I gene expression and synthesis in the colon of rabbits after induction of formalin-immune complex colitis and to determine whether selective blockade of IL-I receptors would reduce the subsequent colonic inflammatory response. Here we report that IL-I is produced just before the sequence of histological events and eicosanoid synthesis characteristic of this colitis model and that specific inhibition of IL-I activity significantly reduces inflammation and necrosis, suggesting that IL-I plays a major role in the pathogenesis of colonic inflammation.
Methods
Rabbit colitis model. Inflammation was induced in the distal colon of male New Zealand rabbits (2.2-2.5 kg) using a modification of the immune complex method of colitis (25, 26) . 4 ml of 0.45% (vol/vol) unbuffered formaldehyde (Electron Microscopy Sciences, Fort Wash-ington, PA) was administered by a catheter inserted 10 cm into the distal colon of anesthetized rabbits (xylazine and ketamine). 2 h later, animals received 0.85 ml of immune complexes in antigen excess through an ear vein. The complexes were prepared by incubating human serum albumin (500 gg/ml) with rabbit antihuman antisera (ICN Immunobiologicals, Costa Mesa, CA), decanting the supernatant, and redissolving the precipitated immune complexes with an albumin solution (6 mg/ml) as described previously (18) .
Time course study. Animals were killed with 40 mg/kg of nembutal (Abbot Laboratories, North Chicago, IL) 0, 4, 12, 24, 48, and 96 h after induction of colitis and the distal colon removed. Longitudinal sections from the last 10 cm of the distal colon were obtained and processed for histologic assessment of inflammation, IL-I mRNA analysis and IL-1 protein measurements. Noninvolved small intestine was also removed for study. Rectal dialysis was performed for 2 h immediately before each time point for measurement of PGE2 and leukotriene B4 (LTB4)' as previously described (18 IL-Ia and IL-I 3 radioimmunoassays. IL-i a and IL-iI3 were measured using specific, non-cross-reacting radioimmunoassays (22) .
These assays were also validated for IL-1 levels after tissue extraction (22) . Longitudinal sections were immediately frozen in liquid nitrogen until assay. At that time, 1 g frozen tissue was thawed and lysed in 10 1. Abbreviations used in this paper: LTB4, leukotriene B4; TNF, tumor necrosis factor. ml PBS containing a cocktail of protease inhibitors (antipain, aprotinin, leupeptin, pepstatin A, all at 1 Ag/ml and PMSF, 1 mM) (Sigma Chemical Co., St. Louis, MO). Tissue was homogenized with an electric homogenizer for 30 s. The homogenate was then centrifuged for 60 min at 100,000 g at 15'C. The supernatant was decanted and assayed directly for IL-la and IL-13 levels. In brief, 100 gl of goat anti-rabbit IL-l, appropriately diluted in assay buffer (0.25% BSA, 0.05% azide, 0.01 M PBS, pH 7.4; anti-IL-la at 1:200,000 and anti-IL-l/3 at 1:6,400) were added to 100 Ml of colon tissue sample, followed by 300 Ml of assay buffer. The tubes were vortexed and incubated overnight at room temperature. '251-IL-lIa or '25I-IL-l 3 (10-12,000 cpm) was then added, the tubes vortexed again and incubated for an additional 24 h at room temperature. 500 Ml of 6% polyethylene glycol (8,000 mol wt), and 2% donkey anti-goat IgG serum (Cambridge Medical Diagnostic, Billerica, MA) diluted in assay buffer were added to precipitate the bound immune complexes from the free '251-IL-1. The samples were vortexed, incubated for 1 h, centrifuged at 2,000 g for 20 min at 4°C, and the supernatants were decanted; the precipitates were counted in a gamma-counter. All samples were tested in duplicate; standard curves were prepared with rabbit recombinant IL-la and IL-1I3. The RIAs have a detection limit of 40 pg/ml and 60 pg/ml for IL-I a and IL-1fl, respectively, at the 95% confidence level (22) . mRNA analysis. Longitudinal sections of distal colon were immediately frozen in liquid nitrogen after dissection. Approximately 0.25 g frozen tissue was lysed in 10 ml of guanidium isothiocyanate solution using an electric homogenizer for 30 s. Total RNA was extracted by centrifugation through 5.7 M CsCl (prepared by dissolving CsCl in 0.1 M EDTA). The RNA pellet was resuspended in 0.25 ml resuspension buffer (5 mM EDTA, 0.5% sarkosyl, and 5% fl-mercaptoethanol) and the concentration determined by ultraviolet at 260/280 nm ratio spectrophotometry. For Northern blot analysis 30 ,ug of total RNA was loaded per lane on a 1.2% agarose gel containing 1.6% formaldehyde. After electrophoresis, the gel was soaked in water for 30 min to remove the formaldehyde and the RNA was transferred to nylon membranes (Hybond-N; Amersham Corp., Arlington Heights, IL) by capillary action and fixed by ultraviolet radiation as described by the manufacturer. The blots were prehybridized for 3-12 h with prehybridization buffer followed by hybridization with the cDNA probes (31, 32) . The rabbit IL-la DNA probe used in these experiments is a 830 bp Eco RI-Bgl II fragment from the IL-la cDNA in pUCl9 (21) . The rabbit IL-I/3 probe is a 830 bp Eco RI-Eco RI fragment of the full length cDNA (21) . Probes Table   I . After the administration of formalin, followed by immune complexes, the distal colon develops acute inflammation. This is characterized by infiltration of neutrophils primarily into the mucosa and submucosa, mucus depletion, crypt abscesses, edema, and scattered areas of mucosal necrosis. Inflammatory (Fig. 1) . IL-1 a tissue concentrations were approximately five times greater than IL-113 levels. Inflammatory index, edema, and percentage of mucosal necrosis correlated with IL-1 a and IL-113 levels. The correlations were r = 0.885 (P < 0.0001), r = 0.789 (P < 0.0001) and r = 0.752 (P < 0.0005) for IL-la (Fig.2 A) and r = 0.706 (P < 0.001), r = 0.792 (P < 0.0001) and r = 0.604 (P < 0.005) for IL-1I (Fig. 2 B) , respectively. Both IL-la and IL-113 were absent in noninflamed small intestinal tissues obtained from the same animals.
IL-ia and IL-i1 gene expression. The transcriptional activation of rabbit IL-1 a and IL-113 mRNA production in the colon during the induction of colitis was examined by Northern blot analysis. The membrane was first hybridized with the probe for rabbit IL-11, stripped, and rehybridized with the rabbit IL-1 a probe. In three separate experiments, we did not observe evidence of IL-1 a or IL-11 mRNA before the onset of colitis (0 h). IL-113 mRNA was clearly observed as early as 4 h after the injection of immune-complexes, whereas IL-1 a mRNA in the same tissue sample was weakly visible. Peak mRNA was present for both IL-l a and IL-1I3 at 12 h. At 96 h there was no evidence of continued presence of IL-1 mRNA. Fig. 3 illustrates the Northern blot of one of the three experiments. IL-1a and IL-113 mRNA was not observed in noninflamed control samples obtained from the small intestine of the same animals.
Production ofcolonic PGE2 and LTB4. The time course of PGE2 and LTB4 production during the induction of colitis is shown in Fig. 4 . No changes in these eicosanoids were observed at 4 and 12 h. A significant increase in colonic PGE2 and LTB4 levels was observed only at 48 and 24 h, respectively. At 96 h, colonic PGE2 and LTB4 production diminished to levels similar to those observed in control rabbits (0 h).
Effects oftreatment with IL-i ra. Treatment of rabbits with human recombinant IL-1 ra significantly reduced inflammatory index from 3.2±0.4 to 1.4±0.3 (P < 0.02), edema from 2.2±0.4 to 0.6±0.3 (P < 0.01) and necrosis from 43±10% to 6.6±3.2% (P < 0.03) compared to vehicle-treated colitis animals (Fig. 5) . Representative macroscopic appearance and histologic sections of distal colons obtained from the two experimental groups are shown in Fig. 6 induce neutrophil-activating protein-l (IL-8) (36-38) and other monocyte-derived chemotactic factors (39) is particularly important since these factors may account for the emigration of neutrophils and monocytes into the injured colon. In addition to IL-8, IL-1 stimulates gene expression of itself, tumor necrosis factor, colony stimulating proteins and IL-2 through IL-6 (1). Therefore, IL-I may be a primary initiator of inflammation as well as be involved in the prolongation of the lesions associated with this model. The ability of the IL-lra to reduce significantly colonic inflammation speaks for the importance of IL-I in both phases of the colitis, but does not rule out the participation of other mediators. Colon IL-a concentrations were five times greater than IL-I levels. In contrast, IL-I B mRNA levels were greater at 4 h and similar to those of IL-a at 12 and 48 h. These results are in accord with other studies in human mononuclear cells where IL-1B mRNA has been found to be predominant (40) , whereas cell-associated IL-a is produced in greater amounts in response to endotoxin stimulation (4, 41, 42) . These observations suggest differences in the regulation ofIL-1 a and IL-I at the transcriptional and translational levels. We have recently shown that IL-a is more potent and more effective than IL-lI# in inducing eicosanoid production in rabbit colon ( 18) . Taken together these data suggest that IL-a may be the predominant form of IL-I produced by the rabbit colon. Preferential production of IL-la has been noted in other tissues and cell types; for example human keratinocytes appear to produce predominantly IL-la (43 Figure 4 . Time course of colonic PGE2 and LTB4 production after administration of immune complexes. PGE2 and LTB4 were measured in rectal dialysates at the time points indicated. PGE2 production was significantly increased only 48 h after the induction of colitis (P < 0.05). LTB4 levels were significantly increased at 24 (P < 0.05) and 48 h (P < 0.02). At 96 h, colonic PGE2 and LTB4 production diminished to levels similar to those observed in control rabbits (P < 0.05). Each point represents the mean±SEM of five rabbits. Figure 5 . Effects of treatment with IL-Ira on inflammation and tissue damage in rabbit immune colitis. IL-i ra (5 mg/kg; n = 8) was administered intravenously 2 h before and 1, 9, 17, 25, 33 h after the immunocomplex administration. Control rabbits (n = 10) were treated with vehicle (0.5 ml PBS). Each bar represents the mean±SEM. Asterisks indicate significant differences between the two groups (*P < 0.02, **P < 0.01, ***P < 0.03). Statistical analysis was performed using the Mann-Whitney two-sample test.
lymphocytes (53) . Related molecules in this family also include macrophage inflammatory proteins some of which are structurally related to IL-8, while others produce different inflammatory effects such as edema and capillary leakage. GM-CSF increases neutrophil superoxide production, which may be involved in tissue damage (54, 55) . IL-l is also an inducer of TNF (56) and IL-6 (57). Although in inducing capillary-leak syndromes (58), PGE2 synthesis (59) and cell death (60) are well established. Thus, the early expression of IL-I in this model suggests a mechanism whereby IL-l initiates a cascade of other cytokines acting independently or synergistically with IL-1.
A role for lipid mediators such as LTB4 and platelet activating factor (PAF) in the induction and enhancement of colon inflammation in experimental colitis has been proposed by several studies (18, (61) (62) (63) . In this study, LTB4 synthesis was documented only 24 h after the induction of colitis and did not correlate with the development of inflammation or necrosis. This suggests that LTB4 production may be a secondary event, possibly a consequence of neutrophil infiltration. One possible sequence of events would be initial synthesis of IL-l followed by expression of IL-8, IL-8 chemotaxis of neutrophils with subsequent production of LTB4 (64) . These data are consistent with our preliminary studies (unpublished observations) in which administration of specific LTB4 receptor blockers or PAF antagonists to rabbits with formalin-immune complex colitis failed to reduce inflammation or tissue damage. However, LTB4 is a potent chemotactic agent for neutrophils and monocytes and could be involved in amplifying the initial inflammatory stimulus.
Although some of the naturally occurring inhibitors of IL-I activity are non-specific (for example, lipoproteins and uromodulin), the existence ofa specific IL-l inhibitor was demonstrated by its ability to block IL-l but not mitogen or IL-2 induced thymocyte proliferation. The initial observation of a specific IL-l inhibitor was made in the sera from human volunteers receiving endotoxin (65) and this was followed by reports of specific IL-1 inhibitory activity in the urine of febrile patients (66) and patients with monocyte leukemia (67) . The urinary inhibitor was partially purified as a 23-kD protein (68) and the mechanism ofits action was shown to be at the level of blocking the binding of IL-1 to T cells and fibroblasts (68) and reduction in biological responses to IL-1 (69) . The production of IL-l inhibitory activity was also shown by human monocytes stimulated with immune complexes (70) and was shown to be specific. This latter report has particular significance for the model of colitis we use. The purification, cloning, and expression of recombinant IL-l inhibitor (23) have provided material to show that it is a pure receptor antagonist with no agonist activity and termed the IL-lra. This protein has allowed us to examine the effects of a specific blockade of IL-1 receptors in the colitis model. (24) . The IL-lra does not bind to murine cell lines expressing the 68-kD receptor. This may suggest that the receptors in rabbit colonic tissue are of the 80-kD type. However, since the IL-Ira shares 26 identical and 40% amino acid homology with IL-Ill and 19 identical and 26% conserved homology with IL-la, the IL-lra may also block the binding of IL-I to the 68-kD rabbit IL-I receptor.
Although the nature ofthe cell targets for the IL-I in the colitis model remains unknown, the present studies establish the effi- cacy of the IL-I ra to block the in vivo activity of IL-1 produced in the colon. Other pro-inflammatory cytokines induced by the immune complexes in colitis are either playing a secondary role or are expressed subsequent to IL-1 synthesis.
